Jean-Paul Kress
CEO at MorphoSys
Meet Jean-Paul Kress
“One lesson from COVID-19 is the idea that scientists in industry, academia, and government can coordinate activities better and work more openly together to rapidly develop transformational medicines in the future. Such collaborations should have impacts far beyond pandemics to provide patients with better treatments for life-threatening diseases such as cancer. At MorphoSys, we’ve learned that including innovative clinical strategies with real-world evidence studies and pursuing accelerated pathways for breakthrough medicines can lead to accelerated drug development and approval.”
Since joining MorphoSys as CEO in September 2019, Kress has strategically repositioned the company from an antibody technology provider to a commercial-stage biopharma company.